Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease.
Site-specific proteolysis is an important regulatory mechanism in many basic cellular processes as well as playing critical roles in the life cycle of viruses and other pathogenic organisms. For the human immunodeficiency virus (HIV) the encoded protease is required for the replication of the virus and has been the target of novel antiviral therapeutics. However, the emergence of inhibitor-resistant viral strains has become an increasingly significant clinical problem. Using a bacteriophage-based genetic selection, a bank of inhibitor-resistant mutants in this protease has been isolated that includes mutations that correlate with resistant clinical isolates. The rapid selection of such mutations has implications for the prediction of relevant mutations and may be applicable to other viral systems.
Sices
H J
HJ
Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Leusink
M D
MD
Pacheco
A
A
Kristie
T M
TM
D010582:Bacteriophage lambda / Q000235:genetics; D003001:Cloning, Molecular / Q000379:methods; D024882:Drug Resistance, Viral / Q000235:genetics; D006678:HIV / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D016333:HIV Protease / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D009154:Mutation / Q000235:genetics; D012641:Selection, Genetic
D017320:HIV Protease Inhibitors; D016333:HIV Protease